LTR Pharma Limited (ASX:LTP)
Australia
· Delayed Price · Currency is AUD 0.3950
+0.0100 (2.60%)
At close: May 2, 2025, 4:00 PM AEST
LTR Pharma Company Description
LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED.
The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
LTR Pharma Limited
| Country | Australia |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
Contact Details
Address: 29/97 Creek Street Brisbane, 4000 Australia | |
| Phone | 61 18 0051 9711 |
| Website | ltrpharma.com |
Stock Details
| Ticker Symbol | LTP |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000305294 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lee Rodne | Executive Chairman |
| Jacques Schipper | Chief Financial Officer |
| Peter McLennan | Chief Operating Officer |
| Prof. Geoffrey A. Strange | Chief Medical Officer |
| Danny Zanardo | Chief Commercial Officer |
| David Hwang | Joint Company Secretary |
| Elizabeth Spooner | Joint Company Secretary |